Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Single-Dose Fluzoparib in Healthy Chinese Subjects
NCT04341077Phase 1Unknown
- Sponsor
- Hengrui
- Start
- Apr 2020
- Primary completion
- Apr 2020
- Modality
- Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of fluzoparib in ovarian cancer, breast cancer, pancreatic cancer (PC) and 1 more, sponsored by Hengrui. Primary endpoints: Time to Maximum Plasma Concentration at Day 4, Maximum Plasma Concentration at Day 4 and 5 more. Status: unknown.
02
Drugs
fluzoparib
03
Conditions
ovarian cancerbreast cancerpancreatic cancer (PC)prostate cancer (PCa)
Beyond the preview
Go deeper on NCT04341077.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04341077.